Cadrenal Therapeutics (CVKD) Liabilities and Shareholders Equity (2022 - 2026)

Cadrenal Therapeutics has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $2.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 64.01% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.3 million (down 38.84% YoY) and the FY2025 annual result came in at $4.3 million, down 57.26% from the prior year.
• Liabilities and Shareholders Equity slipped to $2.9 million in Q1 2026 per CVKD's latest filing, from $4.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $10.1 million in Q4 2024 and troughed at $778174.0 in Q4 2022.
• A 5-year average of $5.7 million and a median of $5.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity jumped 994.77% in 2023, then plunged 64.01% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $778174.0 in 2022, then surged by 994.77% to $8.5 million in 2023, then gained by 18.83% to $10.1 million in 2024, then plunged by 57.26% to $4.3 million in 2025, then plunged by 33.85% to $2.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $2.9 million, $4.3 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.